Buserelin

What it is

Buserelin (Suprefact, Bigonist) is a prescription hormone-suppression drug used to treat prostate cancer, breast cancer, and endometriosis, and to control ovulation timing in IVF cycles. It works by gradually switching off the body's sex hormone production, making it useful wherever estrogen or testosterone drives a disease.

The scientific side

buserelin is a synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone (GnRH, also called LHRH) that is more potent than native GnRH and resistant to enzymatic degradation. Its mechanism of action exploits the pituitary's dependence on pulsatile GnRH signaling: under physiological conditions, pulsatile GnRH pulses stimulate pituitary gonadotroph cells to secrete LH and FSH, which in turn drive gonadal sex hormone production. A single dose of buserelin mimics this pulsatile signal and transiently stimulates LH and FSH release, causing a brief testosterone or estrogen surge (the 'flare') within the first one to two weeks of therapy. However, with continuous or repeated administration, pituitary GnRH receptors undergo prolonged occupancy, become desensitized, and are downregulated — a process called pituitary desensitization or 'medical castration.' The result is a selective and durable inhibition of gonadotropin secretion, leading to testosterone suppression to castrate levels in men and marked estrogen reduction in women. This reversible suppression of sex hormone production is the basis for buserelin's efficacy across hormone-sensitive diseases: in prostate cancer it produces results comparable to surgical orchidectomy; in endometriosis it induces atrophy of endometrial implants by depriving them of estrogen stimulation; in IVF it prevents premature LH surges during controlled ovarian hyperstimulation protocols when used in short or long GnRH agonist protocols. Beyond classical hypothalamic-pituitary-gonadal axis modulation, recent mechanistic work (PMIDs: 39495003, 33586576) has demonstrated that GnRH receptors are expressed on immune cells including regulatory T cells (Tregs) and T helper cell subsets, and that buserelin directly modulates their function — inhibiting Treg immunosuppressive activity via protein kinase A signaling and altering Foxp3/RORγt expression. These immune effects may be relevant to the cancer treatment context and may explain some off-target effects observed during treatment. Pharmacokinetic studies confirm that buserelin is rapidly absorbed after subcutaneous injection and intranasal administration, with the intranasal bioavailability being substantially lower than parenteral routes. Hormone suppression is reversible upon cessation of treatment, with ovarian or testicular function typically resuming within weeks to months.

Class: GnRH receptor agonist — synthetic nonapeptide analog of gonadotropin-releasing hormone; androgen/estrogen deprivation therapy agent

What it's studied for

• Palliative treatment of advanced hormone-sensitive prostate cancer (androgen deprivation therapy) Human RCT
• Endometriosis — suppression of endometrial implants and pain Human RCT
• Controlled ovarian hyperstimulation (COH) and ovulation triggering in IVF/ART cycles Human RCT
• Premenstrual syndrome (PMDD/PMS) — investigational Human observational
• Central precocious puberty (CPP) — immune and endocrine modulation Animal studies only
• Hormone-sensitive premenopausal breast cancer — ovarian suppression Human observational

Safety signals

• Initial testosterone/estrogen flare (tumor flare) — transient worsening of hormone-sensitive symptoms at treatment initiation
• Menopausal-like symptoms (hot flushes, sweating, vaginal dryness) — very common with sustained ovarian or gonadal suppression
• Cardiovascular adverse events — elevated rate in pharmacovigilance data compared with some other GnRH agonists
• Bone mineral density loss and osteoporosis risk — with prolonged sex hormone suppression
• Sexual dysfunction — loss of libido and impotence in men; decreased libido in women
• Headache and nausea — reported in endometriosis treatment cohorts
• Testosterone escape (breakthrough castration failure) during prostate cancer treatment — higher incidence than with goserelin or leuprolide
• Immune dysregulation — alteration of regulatory T cell and T helper cell function via direct GnRH receptor action on immune cells

Community-reported dosing

All studies (4)

• PMID 2106146
• PMID 2109679
• PMID 2506941
• PMID 8862491